Journal Basic Info
- Impact Factor: 1.809**
- H-Index: 6
- ISSN: 2474-1655
- DOI: 10.25107/2474-1655
Major Scope
- Anatomy
- Chemotherapy
- Neurology
- Radiology Cases
- Cardiology
- Hepatology
- Urology Cases
- Orthopedic Sugery
Abstract
Citation: Ann Clin Case Rep. 2017;2(1):1471.DOI: 10.25107/2474-1655.1471
A Case Report of a Patient with HER2-Positive Metastatic Breast Cancer on Dialysis, Who Responded to Ado- Trastuzumab Emtansine
Elia Sais and Sonia Del Barco
University Hospital Doctor Josep Trueta, The Catalan Institute of Oncology (ICO), Medical Oncology Service, Girona, Spain
*Correspondance to: Sonia Del Barco
PDF Full Text Case Report | Open Access
Abstract:
Introduction: Ado-trastuzumab emtansine (T-DM1) is a human epidermal growth factor receptor 2 (HER2)-targeted drug that comprises trastuzumab, a stable linker, and the potent cytotoxic agent derivative of maytansine (DM1). Once T DM1 binds to the HER2 receptor, it allows intracellular drug delivery specifically to HER2-overexpressing cells, minimizing the exposure of the drug to normal tissue.Case: We report the case report of a 47-year old woman with HER2-positive metastatic breast cancer (MBC) on dialysis, which was treated with T-DM1. The tolerance of T-DM1 in this patient was predictable and good and the patient achieved a durable response.Discussion and Conclusions: A previous exploratory analysis has shown that the pharmacokinetic properties of T-DM1 are unaffected by age, race or renal function. However, there are no specific trials for patients with severe renal impairment treated with T-DM1. Only one patient with these characteristics has been treated before with T-DM1, although no dosage recommendation was given.
Keywords:
Antibodies; Antineoplastic agents; Breast neoplasms; Monoclonal; Renal dysfunction
Cite the Article:
Sais E, Del Barco S. A Case Report of a Patient with HER2-Positive Metastatic Breast Cancer on Dialysis, Who Responded to Ado-Trastuzumab Emtansine. Ann Clin Case Rep. 2017; 2: 1471.